Flexion develops local non-opioid therapies for patients with musculoskeletal conditions, postsurgical pain and lower back pain. Its lead product, Zilretta for osteoarthritic knee pain was approved by the FDA in 2017.
Pacira will acquire the company for $8.50 per share in cash, plus one non-tradeable contingent value right worth up to $8 per share in cash. The transaction is expected to close in the fourth quarter of 2021.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
